Literature DB >> 30404716

[Multiple vertebral fractures after denosumab discontinuation].

Louise Tjelum1, Pia Eiken.   

Abstract

Recent reports imply, that denosumab discontinuation may lead to an increased risk of multiple vertebral fractures. This is a case report about two postmenopausal women, both with previous fragility fractures, who presented multiple vertebral fractures after denosumab discontinuation. One of the women also had symptomatic hypoparathyroid hypercalcaemia, six months after denosumab was discontinued. We recommend, that denosumab treatment should not be stopped without considering an alternative treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30404716

Source DB:  PubMed          Journal:  Ugeskr Laeger        ISSN: 0041-5782


  2 in total

1.  Denosumab for the treatment of primary pediatric osteoporosis.

Authors:  A D Anastasilakis; P Makras; A Doulgeraki; S A Polyzos; V Guarnieri; S E Papapoulos
Journal:  Osteoporos Int       Date:  2021-05-13       Impact factor: 4.507

Review 2.  Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.

Authors:  C Camponovo; B Aubry-Rozier; O Lamy; E Gonzalez Rodriguez
Journal:  Osteoporos Int       Date:  2020-10-15       Impact factor: 4.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.